The marijuana industry appears to be heading in a new direction. In a major move by the US Drug Enforcement Administration, an approval was made to cultivate massive amounts of marijuana. The effort aims to provide researchers with vast amounts of marijuana to further study medicinal uses of the drug.
According to the Controlled Substance Act (CSA), the DEA holds the authority to manufacture and produce marijuana. As it stands, the DEA classifies marijuana as a Schedule I drug which is set in accordance to its apparent risk of abuse. Supporters of legal marijuana are aiming to have the DEA reschedule it as a Schedule II drug, making it recognizable for its medicinal benefits. The DEA’s recent support of marijuana research creates optimism among marijuana supporters that it will become a Schedule II drug in the not too distant future.
The DEA’s new proposal sets to increase the Established Aggregate Production Quota for marijuana to 400,000 grams, more than tripling the initial APQ for 2015 which was at 125,000 grams. The increase was in response to the rising demand for cannabidiol (CBD). Cannabidiol is an extracted component of marijuana which is believed to harbor the medicinal effects without the euphoric feeling that’s accredited to THC.
DEA registered manufacturers informed the agency of their need to obtain supplies of CBD to test its medicinal properties. Two particular companies, Insys Therapeutics and GW Pharma, are performing extensive research with CBD and are seeking approval for drugs to treat different types of epilepsy.
Overall, the high demand for CBD demonstrates the governments’ growing interest in marijuana research. At the moment, marijuana is legal in 23 states either medically or recreationally. According to the DEA, the National Institute on Drug Abuse (NIDA) has requested additional supplies of marijuana to be manufactured in 2015 to provide for ongoing and anticipated research efforts involving marijuana. The approved APQ may grow even higher after a Federal Register posting expressed interest earlier this week. The new outlook may rise to the production of 658,000 grams by the end of fiscal year 2015.
To further elaborate on the government’s growing support of marijuana research, a recent report by The Daily Chronicle stated that compliant patients, caregivers and businesses can no longer be arrested or prosecuted by law enforcement in states where marijuana is legal.
The marijuana industry is currently in a transitional period, shifting away from the taboo that once froze research advancements, allowing those who embraced its benefits to be imprisoned and persecuted. The ultimate goal for federal legalization is no longer a far-fetched dream as more government officials realize the financial and medical benefits linked to marijuana. By protecting those who solely seek to use marijuana in accordance with the law, the country is gradually progressing to a new day that will present imperative treatment options for many individuals in need.
Since 2010, BioTrack has provided the legal cannabis operators with the industries’ leading seed to sale tracking and dispensary point of sale software. Whether you operate a cultivation site, manufacturing and processing facility, medical or recreational dispensary or a business that covers the full vertical, we’ve got you covered when it comes to compliance.
Our extensive seed-to-sale software allows licensed operators to remain compliant while helping to identify key data points to streamline and optimize inventory management at each phase of the operation; cultivation, processing, destruction and waste, transportation, lab testing and dispensing.
Along with BioTrack’s best-in-class commercial software, we also provide government track and trace solutions and currently hold government contracts in nine states. This allows lawmakers and regulatory agencies to ensure a transparent and compliant program from top to bottom.
In 2021 BioTrack became a part of Forian, Inc. Forian is a Delaware corporation created by the combination of Helix Technologies, Inc. (“Helix”) and Medical Outcomes Research Analytics, LLC (“MOR”). As of March 2, 2021, each of Helix and MOR are wholly owned subsidiaries of Forian. Forian represents the unique intersection of a leading cannabis technology platform with intelligent data science yielding the combined power to drive innovation and transparency across the healthcare and cannabis industries. For more information, see our website, which remains in process.
Are you interested in learning more about BioTrack or the cannabis industry in general? Check out our careers page to learn more about what it takes to join our winning team or take a look at our industry-leading blog for great news and information about the cannabis industry.